CJC-1295 (No DAC) – Lyophilized Peptide

Product Overview

CJC-1295 (No DAC), also known as Mod GRF 1-29, is a synthetic analog of growth hormone-releasing hormone (GHRH). It is widely studied for its role in stimulating the natural pulsatile release of growth hormone (GH) through interaction with the pituitary gland.

Unlike the DAC-modified version, this form has a shorter half-life, making it particularly useful in research protocols focused on mimicking the body’s natural GH release patterns.

This product is supplied as a lyophilized (freeze-dried) powder, intended strictly for laboratory and research use.

Research Profile

CJC-1295 (No DAC) is structurally derived from the first 29 amino acids of endogenous GHRH, with modifications that enhance stability while preserving biological activity.

In research settings, it binds to GHRH receptors in the anterior pituitary, promoting controlled GH secretion in a pulsatile manner. Its shorter duration of action allows for more precise timing and control in experimental protocols compared to long-acting variants.

Areas of Research Interest

Research involving CJC-1295 (No DAC) has explored its potential role in:

Growth hormone pulsatility and regulation
Sleep architecture and recovery cycles
Lean body mass and metabolic studies
Tissue repair and regenerative signaling
Anti-aging and longevity pathways
Synergistic peptide protocols (e.g., with Ipamorelin)

Key Characteristics

GHRH analog (Mod GRF 1-29)
Short half-life for controlled pulsatile research
Supports natural GH release patterns in studies
Often used in combination with GH secretagogues (e.g., Ipamorelin)
Allows for precise timing in experimental applications

Format & Specifications

Compound: CJC-1295 (No DAC) / Mod GRF 1-29
Form: Lyophilized powder
Purity: ≥ 99%
Quantity: 5 mg
Storage: Store in a cool, dry place. Refrigerate after reconstitution

Important Notice

This product is intended for research and laboratory use only.

Not for human consumption
Not intended to diagnose, treat, cure, or prevent any disease
Not approved by Health Canada or the FDA for medical use
Must be handled by qualified professionals in a controlled research environment

Optimize Your Research Protocol CJC-1295 (No DAC) is commonly studied alongside Ipamorelin to explore synergistic effects on growth hormone signaling and pulsatile release dynamics.

Why Choose ARx Supplements

At ARx Supplements, we prioritize:

High-purity compounds sourced from trusted manufacturers
Rigorous third-party testing standards
Consistent, professional-grade formulations
Transparent and reliable supply for research professionals